Unmet Needs

Cancer is a devastating disease. Immunotherapy can harness the body’s immune system to fight cancer.

Immune checkpoint inhibitors are revolutionary immunotherapy drugs; however, the response rates in some cancer types are still very low.

Addressing unmet needs, our cutting-edge science focuses on innovative antibodies to fine-tune the immune network in cancer.

Cutting-Edge Science

Key Products

Strong anti-tumor activity and minimal RBC binding

Unique Design

  • High-affinity binding to CD47 on tumor cell
  • Unique binding epitope on RBC hindered by membrane glycosylation

Key Differentiation

  • Good safety profile
  • No priming dose required
  • No “sink effect”
  • Anti-tumor activity in MDS, AML, and NHL

Selected Publications

Unique Design

Unique intra-dimer binding through a C-terminus epitope of CD73 on tumor cell

Key Differentiation

  • Complete CD73 inhibition without the “hook effect”
  • Inhibition by a non-competitive manner, full target occupancy and sustained blockade compared to small-molecule inhibitor
  • Potentially superior anti-tumor activity, especially in an adenosine-rich tumor micro-environment

Unique Design

Immune activation only upon tumor engagement

Key Differentiation

  • Immune response targeted towards tumor cells, with minimal systemic toxicity
  • Better efficacy than Claudin 18.2 or 4-1BB monotherapy, or combo

Selected Publications

AI Design

AI-guided novel biologics synthesis


Cell-penetrating antibody for intracellular target

mRNA Technology

Antibody synthesis in-vivo with mRNA


Local activation of masked antibody by tumor-specific protease at tumor site

4-1BB Platform

Modular 4-1BB engaging bi-specific antibody platform